BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Recruiting · Phase 2 · NCT06854003
Conditions: Mantle Cell Lymphoma, Lymphoma
At a glance
- Research payments reported, 2025
- $317,726
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Christine Ryan (with BeiGene)
- Tested
- Bendamustine (drug), Rituximab (drug), Cytarabine (drug), Zanubrutinib (drug), Sonrotoclax (drug)
- Dates
- Started 2025-04-22; completion 2039-11-01
- Results posted
- Not yet
This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL). The names of the study drugs involved in this study are: * bendamustine (a type of alkylating agent) * rituximab (a type of monoclonal antibody) * cytarabine (a type of antineoplastic) * zanubrutinib (a type of kinase inhibitor) * sonrotoclax (a type of BCL2 inhibitor)
From ClinicalTrials.gov, last updated 2026-02-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $317,726 in research payments for this study in 2025 (1 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $317,726
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.